Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

While Moderna was viewed as a front-runner in the race for a Covid-19 vaccine, competition is mounting. On Monday, Oxford University, which is developing a Covid-19 vaccine candidate along with AstraZeneca, published some positive data on phase 1/2 trials, indicating that the vaccine was.

Should Oxford-AstraZeneca’s Progress Worry Moderna?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to report second quarter 2020 financial results on Wednesday, August 5, 2020.

Moderna to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020

Johnson & Johnson

Novavax

Pfizer

Vaxart

The U.S. government is pouring money into coronavirus vaccine development, and a handful of companies are cashing in.

Everything You Need to Know About Operation Warp Speed's Coronavirus Vaccine Accelerator

Amgen

Haemonetics

Netflix

Increasingly, the Wall Street firms we cover agree that while the future is still bright for the U.S.

4 First-Half Growth Stock Winners Are Top Picks for the Rest of 2020

BioNTech SE

New research could mean the market opportunity for COVID-19 vaccines might be bigger than expected. Or maybe not.

Could These Findings Dramatically Change the Opportunities for COVID-19 Vaccine Stocks?

Merck

Drug company executives insisted Tuesday they aren’t cutting corners in fast-tracking development of potential vaccines to prevent infection of the coronavirus.

Pharma executives promise Congress they aren't cutting corners in fast tracking coronavirus vaccine

Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.

3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data

Attaining a new fast-track designation for a vaccine is often beneficial for a company’s shareholders in the short term, but it also implies intensified organizational and scientific challenges.

What Does It Mean for Investors When a Coronavirus Vaccine Is "Fast-Tracked"?

Some of the companies pursuing a coronavirus vaccine will end up far more valuable than they are today -- while others might be a disaster waiting to happen.

Beware! Your Coronavirus Stock Might Be Crushed by the FDA

Top executives at Moderna boosted the number of shares they're selling after the biotech reported positive results for its COVID-19 vaccine candidate.

Should Investors Worry About Moderna Insiders' Increased Stock Sales?

Market participants still aren't sure what to expect as earnings season continues.

Markets Open Mixed Monday Morning; AstraZeneca Reveals COVID-19 Vaccine Data While Moderna Gets Downgraded

JPMorgan has downgraded shares in COVID-19 vaccine maker Moderna’s stock over valuation concerns. The drop is from overweight to neutral.

Here’s why JPMorgan just downgraded Moderna stock, despite COVID vaccine mania

Moderna stock fell Monday on a downgrade after an analyst suggested the coronavirus vaccine maker is overvalued. He now has a neutral rating on MRNA stock, down from overweight.

Moderna Plunges On Downgrade — Is Coronavirus Vaccine Maker Overvalued?

Analysts at J.P. Morgan downgraded shares of Moderna Inc. MRNA, +15.93% to neutral from overweight over concerns about the valuation of the preclinical company, which has never produced an approved product.

J.P. Morgan downgrades Moderna over valuation concerns

GlaxoSmithKline

Inovio Pharmaceuticals

Sinovac Biotech

Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.

Here Are All the COVID-19 Vaccines Currently in Clinical Testing

The 1 Number Healthcare Investors Should Consider When a Company Releases Study Results

A coronavirus vaccine has the potential to not only save countless lives, but also to mitigate trillions in economic damage.

Which Biotech Company Has the Most Promising Coronavirus Vaccine?

America's highest-profile medical professional waxes optimistic on the potential for a "safe and effective" vaccine by 2021.

Coronavirus Vaccine Developers Rise After Fauci's Comments

Twenty-seven nations are racing to lock in a chance to buy its promising coronavirus vaccine candidate.

Why Moderna Stock Soared to a New All-Time High Today

Intuitive Surgical

Nasdaq Rises 29 as Intuitive Surgical Defies Robotic Surgery Competition; Moderna Jumps Again on Coronavirus Vaccine Prospects

Encouraging news coming out of the biotech regarding its coronavirus vaccine candidate caused its stock to pop.

Why Moderna Stock Just Went Up

Sanofi

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna , Sanofi and Johnson & Johnson as well as biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines

Gilead Sciences

The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy.

BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies

Kirkland Lake Gold

Virgin Galactic

Debt-free and in the limelight, strong fundamentals mean these companies have ample financial headroom for aggressive growth.
The post 4 Debt-Free Companies With Strong Stocks to Buy appeared first on InvestorPlace.

4 Debt-Free Companies With Strong Stocks to Buy

Quest Diagnostics

Labcorp Holdings Inc

Regeneron Pharmaceuticals

COVID-19 crushed the stock market in March. The only real survivors were companies involved with testing, treatments and vaccines.

News for Moderna Stock (MRNA)